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Abstract
Objective: To compare the efficacy and safety of intra-
venous ferric carboxymaltose (FCM) with first-line oral 
ferrous sulfate (FS) in pregnant women with iron defi-
ciency anemia (IDA).
Materials and methods: Pregnant women (n = 252; gesta-
tional weeks 16–33) with IDA were randomized 1:1 to FCM 
(1000–1500 mg iron) or FS (200 mg iron/day) for 12 weeks. 
The primary objective was to compare efficacy; secondary 
objectives included safety and quality of life.
Results: Hemoglobin (Hb) levels improved at compara-
ble rates across both treatments; however, significantly 
more women achieved anemia correction with FCM vs. FS 
[Hb  ≥ 11.0 g/dL; 84% vs. 70%; odds ratio (OR): 2.06, 95% 
confidence interval (CI): 1.07, 3.97; P = 0.031] and within 
a shorter time frame (median 3.4 vs. 4.3 weeks). FCM 
treatment significantly improved vitality (P = 0.025) and 
social functioning (P = 0.049) prior to delivery. Treatment-
related adverse events were experienced by 14 (FCM; 11%) 
and 19 (FS; 15%) women, with markedly higher rates of 
gastrointestinal disorders reported with FS (16 women) 
than with FCM (3 women). Newborn characteristics were 
similar across treatments.
Conclusions: During late-stage pregnancy, FCM may be a 
more appropriate option than first-line oral iron for rapid 
and effective anemia correction, with additional benefits 
for vitality and social functioning.
Keywords: Clinical trial; ferric carboxymaltose; hemo-
globin; intravenous; iron deficiency anemia; newborn; 
pregnancy; quality of life; serum ferritin.
Introduction
Pregnancy significantly increases the need for iron; the 
dramatic physiological changes of the mother and the 
increasing demands of the growing fetus lead to major 
maternal hematological changes, of which increased red 
blood cell mass and, in the third trimester, expansion of 
blood volume are key [1–3]. This increased demand for iron 
subsequently places the mother and infant at risk of devel-
oping iron deficiency anemia (IDA), which can lead to ges-
tational complications, as well as increased maternal and 
infant morbidity and mortality [4–7]. This risk is a global 
phenomenon and the prevalence of anemia in pregnant 
women is high, affecting 41.8% of all pregnant women 
worldwide [8]. Such high prevalence indicates that, by 
and large, dietary uptake of iron is insufficient to meet 
 physiological demands during pregnancy [3], and effective 
management of IDA in pregnancy is currently lacking.
Oral iron is routinely used to treat IDA in pregnant 
women. However, this can often lead to gastrointestinal 
side effects, such as nausea, diarrhea or vomiting, that 
impact on the adherence to and, ultimately, the efficacy 
of the iron treatment [5, 9, 10]. In those women who do 
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not respond to, are non-compliant with, or are unable to 
tolerate oral iron treatment, intravenous (IV) iron prepa-
rations may provide a better option [9–11]. As such, IV iron 
preparations are increasingly being recommended for 
women with severe IDA and when IDA is diagnosed later 
in pregnancy and rapid intervention is required [9, 11, 
12]. IV preparations can deliver a larger iron supply more 
rapidly than oral iron and, because of the route of admin-
istration, bypass the risk of gastrointestinal side effects. 
However, among currently available IV iron preparations, 
some require multiple doses [5], some require long infu-
sion times, while others have very little data published on 
proven clinical benefit versus risks.
Ferric carboxymaltose (FCM; Ferinject®) is a dextran-
free IV iron preparation that allows rapid administration of 
high single doses of iron (up to 1000 mg iron in 15 min) once 
a week. FER-ASAP (FERric carboxymaltose – Assessment of 
SAfety and efficacy in Pregnancy) was the first randomized, 
controlled trial to assess FCM in pregnant women with IDA.
Methods
Participants
Pregnant women aged  ≥ 18 years, in their second or third trimester (ges-
tational weeks 16–33) and with serum ferritin levels   ≤  20 ng/mL and IDA 
[defined as hemoglobin (Hb) 8.0–10.4 g/dL for gestation weeks 16–26 
or Hb  ≤  11.0 g/dL for gestation weeks 27–33] were eligible for this study. 
Women were excluded if they had a significant bleed or surgery within 
3 months prior to screening, received a blood transfusion, erythropoi-
etin treatment, oral iron (unless the dose was   ≤  100 mg iron per day) or 
parenteral iron treatment during the month prior to screening, or were 
anticipated to need a blood transfusion during the study period. Other 
exclusion criteria included anemia that was not caused by iron defi-
ciency (ID) or was related to other acute or ongoing disorders, multiple 
pregnancies, fetal abnormalities evident on ultrasound, or any serious 
medical condition that may prevent completion of the trial.
Study design
FER-ASAP was an international, Phase IIIb, open-label study in which 
pregnant women were randomized 1:1 to receive IV FCM (Ferinject®; 
1000–1500  mg iron) or oral ferrous sulfate (FS; Plastufer®; 100  mg 
capsules taken twice daily; total daily dose 200 mg iron) (ClinicalTri-
als.gov identifier: NCT01131624). FCM dosing regimens were strati-
fied according to body weight (Table 1) in order not to exceed a dose 
of 15  mg iron per kg of body weight per single dose, with all infu-
sions to be completed by week 3. Oral FS was to be taken daily for 12 
weeks. This study was conducted in accordance with the principles 
of the Declaration of Helsinki and Good Clinical Practice guidelines, 
and institutional review boards or independent ethics committees of 
all investigational sites approved the protocol. All study participants 
provided written informed consent prior to enrollment.
Table 1: Ferric carboxymaltose administration schedule. 
Baseline Hb 
(g/dL)
 
 
Body weight   
 < 66 kg  ≥ 66 kg
8.0–9.0   3 × 500 mg iron within 
2 weeks of baseline
  1 × 1000 mg iron, followed by 
1 × 500 mg iron 1 week later
9.1–10.5/11.0  2 × 500 mg iron within 
2 weeks of baseline
  1 × 1000 mg iron
Hb = Hemoglobin.
Study objectives and assessments
The primary objective was to compare the efficacy of IV FCM with oral 
FS as treatment of IDA in pregnant women during their second and 
third trimesters. Secondary objectives were to determine the safety 
and tolerability of FCM in pregnant women and their newborns, and 
to determine the relationship between iron status and women’s qual-
ity of life.
Efficacy assessments were performed at baseline, weeks 3, 6, 9, 
and 12 and/or prior to delivery (whichever came first; samples prior 
to delivery could be taken at any point after week 3). The primary 
efficacy endpoint was the change in Hb from baseline to week 3. Sec-
ondary efficacy endpoints were change in Hb and other serum iron 
parameters, the proportion of women who achieved anemia cor-
rection (defined as Hb   ≥ 11.0 g/dL), and time to anemia correction. 
Changes in quality of life were also evaluated: the 36-item short-form 
(SF-36) health survey was completed at baseline, week 3 and prior 
to delivery. Safety was monitored throughout and comprised the 
incidence of treatment-emergent adverse events (TEAEs; defined as 
an adverse event that occurred or increased in severity after the first 
dose of medication was administered) and treatment-related TEAEs, 
coded according to the Medical Dictionary for Regulatory Activities 
(version 16.1). Changes in routine hematological and biochemical 
laboratory parameters, physical examinations and vital signs were 
also evaluated at the same time as efficacy assessments. Apgar scores 
and other newborn parameters were also assessed. Newborns deliv-
ered at hospitals that were not participating in this study were not 
assessed. Blood samples were taken using standard venipuncture 
techniques and clinical laboratory parameters [Hb, serum ferritin, 
total iron binding capacity, serum iron, transferrin saturation (TSAT), 
soluble transferrin receptor] were assessed by an independent labo-
ratory.
Statistical analysis
A sample size of 120 women per treatment arm was considered suf-
ficiently powered to detect cross-group differences in Hb levels at 
week 3 versus baseline (α = 0.05, two sided; 90% power). The sample 
size was increased to 125 women per treatment arm to account for 
low expected discontinuation at week 3; therefore, the total planned 
study population size was 250.
Efficacy analyses were conducted on the full analysis set (intent 
to treat), which comprised all randomized women who received at 
least one dose of study treatment and had at least one efficacy assess-
ment available at baseline and within the study period. The primary 
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efficacy endpoint was analyzed using an analysis of covariance 
(ANCOVA) model with factors for treatment, pooled countries [South 
Korea, Russia, rest of the world (Australia, Singapore, Sweden, Swit-
zerland and Turkey)] and baseline Hb level; changes in Hb and other 
serum iron parameters at weeks 6, 9, and 12 and delivery were also 
analyzed using this model. Logistic regression, including the same 
factors accounted for in the primary efficacy analysis, was used to 
compare the proportions of women achieving anemia correction, and 
an unstratified log-rank test was used to explore the time to anemia 
correction. SF-36 domain scores were calculated using the algorithms 
provided within the SF-36 documentation and analyzed as for the pri-
mary efficacy endpoint. Safety data were summarized descriptively; 
the safety population comprised all women who received at least one 
dose of study treatment. Data from newborns were also summarized 
descriptively. For all analyses, missing data were treated as missing – 
no imputation was performed.
Results
Patients
Between November 2010 and May 2014, 252 pregnant 
women [median age 31  years (range 27–35)] from 29 
centers across seven countries were randomized to IV 
FCM (n = 126) or oral FS (n = 126) (Figure  1). The majority 
of participants (88%) completed the study, with similar 
withdrawal rates between the treatment arms (Figure 1). 
Most withdrawals from the study were because of volun-
tary discontinuation by the participant (8 women treated 
with FCM and 6 with FS); one woman treated with FCM 
Screening (n=774)Enrollment
Excluded (n=522)
Randomized (n=252)
    Australia (n=8)  Sweden (n=14)  
    Russia (n=124)  Switzerland (n=9)
    Singapore (n=3)  Turkey (n=4)  
    South Korea (n=90)
Randomized to ferric carboxymaltose (n=126)
    Received ferric carboxymaltose (n=123)
    Did not receive ferric carboxymaltose (n=3)
Randomization
Follow-up
Analysis
Randomized to ferrous sulfate (n=126)
    Received ferrous sulfate (n=124)
    Did not receive ferrous sulfate (n=2)
Completed study (n=111)
Discontinued ferric carboxymaltose by end of 
study (n=15)
    TEAE (n=1)
    Voluntary discontinuation (n=8) 
    Protocol deviation (n=1)
    Lost to follow-up (n=4)
    Other (n=1)
Completed study (n=110)
Discontinued ferrous sulfate by end of study 
(n=16)
    TEAE (n=7)
    Voluntary discontinuation (n=6)
    Protocol deviation (n=1) 
    Lost to follow-up (n=2) 
Full analysis set (n=121)
    No study medication taken (n=3)
    No baseline and evaluable post-baseline 
    efficacy assessment (n=2)
    Safety analysis set (n=123)
    No study medication taken (n=3)
Full analysis set (n=115)
    No study medication taken (n=2)
    No baseline and evaluable post-baseline 
    efficacy assessment (n=9)
    Safety analysis set (n=124)
    No study medication taken (n=2)
Figure 1: Participant disposition.
TEAE= treatment-emergent adverse event.
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and seven treated with FS withdrew because of TEAEs 
(Figure 1). Participant demographics and baseline charac-
teristics were generally balanced between the treatment 
arms and were representative of the target population 
(Table 2). Samples for the time point of last visit prior to 
delivery were taken a median of 14.5 (range 2–93) days 
before delivery for the FCM group and 15.0 (range 2–85) 
days before delivery for the FS group. By week 12, many of 
the participating women had already given birth; as such, 
there are limited data for the hematological assessments 
at this time point.
Efficacy
Hb levels improved with both study treatments at each 
visit throughout the assessment period (Figure 2). Mean 
changes in Hb for the FCM group were consistently 
superior to mean changes in Hb for FS (change in Hb 
at week 3: 1.23±0.95 g/dL vs. 0.96±1.38 g/dL, respec-
tively), although statistical significance was not reached 
at week 3 [least-squares mean: 1.16 vs. 1.04; difference: 
0.12, 95% confidence interval (CI): –0.10, 0.34; P = 0.274; 
repeated-measures model]; therefore, the primary effi-
cacy endpoint was not met at week 3. However, a sta-
tistically significant improvement in mean change in 
Hb levels from baseline was achieved for FCM vs. FS at 
week 6 (change in Hb: 1.75±1.18 g/dL vs. 1.32±1.54 g/dL; 
least-squares mean: 1.68 vs. 1.40; difference: 0.28, 95% 
CI: 0.02, 0.55; P = 0.032; repeated-measures model). Preg-
nant women treated with FCM were twice as likely to 
achieve anemia correction (Hb   ≥ 11.0 g/dL) than those 
treated with FS [84% (n = 101) vs. 70% (n = 80); odds ratio 
(OR): 2.06, 95% CI: 1.07, 3.97; P = 0.031], and the median 
time to achieving this correction was shorter with FCM 
treatment (3.4 vs. 4.3 weeks).
Comparative analysis of other hematological parame-
ters revealed sustained, significantly greater increases in 
serum ferritin levels with FCM treatment compared with FS 
(Figure 3A). Similar TSAT levels between treatment arms 
were seen up to the week 9 assessment; however, at week 
12 and prior to delivery, TSAT levels were significantly 
greater with FS treatment (Figure 3B). Soluble transfer-
rin receptor levels decreased with both treatments, with 
Table 2: Participant demographics and baseline characteristics (safety analysis set). 
  Ferric carboxymaltose 
(n = 123)
  Ferrous sulfate 
(n = 124)
Age, median (range), years   31 (18–44)  31 (19–52)
Age category, n (%)
  < 36 years   91 (74)  100 (81)
  ≥ 36 years   32 (26)  24 (19)
Race, n (%)
 White   73 (59)  76 (61)
 Black/African American   1 (1)  3 (2)
 Asian   47 (38)  45 (36)
 Other   2 (2)  0 (0)
Pre-pregnancy weight, mean (SD), kg   59.3 (11.6)  57.4 (10.7)
Pre-pregnancy BMI, mean (SD), kg/m2   22.1 (3.7)  21.6 (3.5)
Baseline weight, mean (SD), kg   66.9 (12.4)  65.5 (11.2)
Baseline weight category, n (%)
  < 66 kg   69 (56)  68 (55)
  ≥ 66 kg   54 (44)  56 (45)
Baseline Hb level, mean (SD), g/L   98 (0.8)  99 (1.2)
Baseline Hb level category, n (%)
   ≤  9.0 g/dL   22 (18)  17 (14)
  > 9.0 g/dL   101 (82)  106 (86)
Baseline serum ferritin level, mean (SD), ng/mL   12.15 (35.3)  12.35 (32.0)
Gestational age category, n (%)
  < 16 weeks   0 (0)  0 (0)
 16– < 20 weeks   12 (10)  9 (7)
 20– < 33 weeks   105 (85)  110 (89)
  ≥ 33 weeks   6 (5)  5 (4)
Percentages calculated according to treatment group.
BMI = body mass index, Hb = hemoglobin, SD = standard deviation.
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Week 12 Prior
to delivery
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P=0.203P=0.559
*P=0.032
P=0.274
P=0.118 FCM (n=121)
FS (n=115)
*Indicates the P value is significant at the α=0.05 level
Figure 2: Change in hemoglobin levels.
FCM = ferric carboxymaltose, FS = ferrous sulfate, Hb = hemoglobin, SD = standard deviation.
significantly greater decreases with FCM treatment at 
weeks 6 and 9 (Figure 3C).
Quality of life
According to the SF-36 health survey, FCM treatment led 
to significant, clinically relevant improvements over FS 
in vitality prior to delivery (mean score change±standard 
deviation: FCM, 6.51±21.90; FS, 2.34±22.09; least-squares 
mean: 5.67 vs. –0.23; difference: 5.90, 95% CI: 0.75, 11.04; 
P = 0.025) (Figure 4A). Significant improvements in social 
functioning were also evident prior to delivery following 
FCM vs. FS treatment (FCM, 3.03±23.61; FS, –2.50±24.55; 
least-squares mean: 3.28 vs. –2.49; difference: 5.77, 95% 
CI: 0.01, 11.51; P = 0.049) (Figure 4B).
Safety and tolerability
The median (range) total dose administered was 1000 (2–
1500) mg for FCM and 12,300 (200–20,500) mg for FS. One 
patient received only 2  mg of FCM; administration was 
interrupted due to bronchospasm and the patient with-
drew on day 6. One patient who received only 200 mg of 
FS withdrew due to nausea on day 4.
The incidence of TEAEs was similar between the treat-
ment arms: in the FCM group, 60 women (49%) expe-
rienced 165 TEAEs; in the FS group, 50 women (40%) 
experienced 105 TEAEs. The majority of events were mild 
in intensity (Table  3). Overall, the most common TEAEs 
were nausea (6%), headache (5%) and dyspepsia (4%), 
and the most common TEAEs according to system organ 
class were “pregnancy, puerperium and perinatal condi-
tions” in the FCM group [32 events in 26 women (21%)] and 
“gastrointestinal disorders” in the FS group [42 events in 
25 women (20%)]. The most common treatment-related 
TEAEs were headache with FCM [experienced by 4 women 
(3%)] and nausea with FS [in 6 women (5%)], and markedly 
higher rates of gastrointestinal disorders were reported 
with FS treatment (in 16 women) compared with FCM 
treatment (3 women) (Table 4). Serious TEAEs occurred in 
23 women treated with FCM (26 events) and in 10 women 
treated with FS (11 events); all were single events, except 
for “failed trial of labor”, “fetal distress syndrome”, “pre-
mature delivery”, “premature rupture of membranes” 
and “threatened labor”, each of which occurred in two 
women treated with FCM, and “premature labor”, which 
occurred in three women treated with FS (pre-eclampsia 
was also reported to have occurred twice in one woman 
treated with FS). One serious TEAE, “bronchospasm”, 
which was treatment related, led to discontinuation of 
FCM; this event was of moderate intensity and resolved on 
the same day after withdrawal of study treatment. Seven 
women discontinued treatment with FS because of gas-
trointestinal TEAEs (n = 5), syncope (n = 1) and rash (n = 1). 
No hypophosphatemia TEAEs were reported during this 
study. Eleven women (FCM, n = 10; ferrous sulfate, n = 1) 
recorded phosphate levels below the lower normal range 
threshold [0.6  mmol/L (2 mg/dL)]; these decreases were 
largely observed at week 3 and recovered in all the women 
to within the normal range by the end of the study, indi-
cating no clinical relevance of these findings.
Newborn status
Apgar scoring was similar between treatment groups. 
The overall mean Apgar score of the newborns at the first 
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Figure 3: Changes in other hematological parameters: (A) serum ferritin; (B) transferrin saturation; (C) soluble transferrin receptor.
FCM = ferric carboxymaltose, FS = ferrous sulfate, SD = standard deviation, SF = serum ferritin, sTfR = soluble transferrin receptor, TSAT = trans-
ferrin saturation.
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Figure 4: Changes in SF-36 component scores: (A) vitality; (B) social functioning.
FCM = ferric carboxymaltose, FS = ferrous sulfate, SF-36 = 36-item short-form health survey.
Table 3: Treatment-related TEAEs by severity.
Treatment-related 
TEAE severity, number 
of patients (%)
  Ferric 
carboxymaltose 
(n = 123)
  Ferrous 
sulfate 
(n = 124)
Total   60 (49)  50 (40)
 Mild   43 (72)  28 (56)
 Moderate   17 (28)  20 (40)
 Severe   0 (0)  2 (4)
TEAE = treatment-emergent adverse event.
minute following birth was 8.3, increasing to 9.1 at 5 min, 
with all achieving an Apgar score of 10 by 10  min after 
birth. Other newborn characteristics were also similar 
between treatments (Table  5). Independent of the moth-
er’s cord serum ferritin levels, all newborns were assessed 
to have normal serum ferritin levels.
Discussion
Our study demonstrates that IV FCM is effective and well 
tolerated in pregnant women with IDA during late-stage 
pregnancy and that women using this treatment give birth 
to healthy newborns. The increases in Hb levels were 
comparable between treatment arms in this study popula-
tion. Although the primary efficacy endpoint was not met 
(FCM did not show superiority at week 3), this treatment 
did improve Hb levels to a significantly greater extent 
than oral iron by week 6 (P = 0.032). Furthermore, we have 
demonstrated that FCM more rapidly and more effectively 
established normalized Hb levels (Hb  ≥ 11.0 g/dL) and was 
significantly more effective at replenishing iron stores 
than FS.
In preparation for childbirth, Hb levels are known to 
rise as pregnancy progresses and peak before delivery [5]. 
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Table 4: Treatment-related TEAEs (experienced by  ≥ 2 patients overall) by MedDRA primary system organ class and preferred term.
Treatment-related TEAE,a number of patients (%)   Ferric carboxymaltose 
(n = 123)
  Ferrous sulfate 
(n = 124)
Total   14 (11)  19 (15)
Nervous system disorders   7 (6)  1 (1)
 Headache   4 (3)  1 (1)
 Dizziness   3 (2)  0 (0)
 Dysgeusia   2 (2)  0 (0)
General disorders and administration-site conditions  4 (3)  0 (0)
 Vascular disorders   2 (2)  0 (0)
Gastrointestinal disorders   3 (2)  16 (13)
 Nausea   2 (2)  6 (5)
 Vomiting   0 (0)  2 (2)
 Constipation   0 (0)  3 (2)
 Diarrhea   0 (0)  4 (3)
 Abdominal pain upper   0 (0)  5 (4)
 Dyspepsia   0 (0)  3 (2)
aAccording to physician’s assessment; a single patient could appear in multiple classes. Percentages calculated according to treatment 
group.
MedDRA = Medical Dictionary for Regulatory Activities (version 16.1), TEAE = treatment-emergent adverse event.
Table 5: Newborn characteristics (safety analysis set).
  Ferric carboxymaltose 
(n = 112)
  Ferrous sulfate 
(n = 109)
Birth weight, mean (SD), kg   3.4 (0.5)  3.4 (0.5)
Birth length, mean (SD), cm   50.8 (2.6)  50.7 (3.0)
Birth weight/length ratio, mean (SD), kg/cm   0.067 (0.008)  0.067 (0.008)
Cord Hb level, mean (SD), g/dL   14.8 (1.9)  14.6 (1.7)
Cord hematocrit, mean (SD), ratio   0.5 (0.1)  0.5 (0.1)
Cord serum ferritin level, mean (SD), ng/mL   255.6 (187.2)  236.7 (135.9)
Hb = hemoglobin, SD = standard deviation.
The loss of blood at childbirth can be considerable – it is 
the most common cause of postpartum anemia – there-
fore, sufficient iron stores are of particular importance 
during delivery and the postpartum period to overcome the 
recurrence of ID/IDA in the mother [1, 13, 14] and newborn 
[1]. In this study, however, mean Hb levels appeared to be 
lower at the prior-to-delivery time point than at week 12 
for both the FCM and the FS groups, inferring a decrease 
in Hb levels immediately prior to delivery. It is important 
to note that, because many women had already given birth 
by week 12 of this study, patient numbers for all hemato-
logical parameter assessments were lower at week 12 than 
at the prior-to-delivery time point. As a result, caution is 
warranted in interpreting week 12 data in the context of 
the other assessment time points. Furthermore, measure-
ments prior to delivery were taken approximately 2 weeks 
before birth and therefore may not reflect the peak levels 
seen at delivery.
A conservative FCM treatment regimen was used for 
this study. This was based on dosage calculations accord-
ing to the original label (with each single dose not to 
exceed 15 mg iron per kg of body weight); more recently, 
a single higher dosage of FCM (20 mg iron per kg of body 
weight) has been approved [15]. Use of the lower dose of 
FCM in our study may have impacted on the outcomes and 
it must be considered that use of a higher dose, in accord-
ance with the current label, may lead to greater efficacy. 
Our study is the first to compare FCM with FS in pregnant 
women; as such, confirmatory data are lacking in this 
particular patient population. However, FCM treatment 
in postpartum women has been comprehensively inves-
tigated and evidence from three large randomized con-
trolled trials performed across Europe and North America 
support our findings: FCM was found to be at least as 
effective as FS at increasing Hb levels, and it showed 
superiority in providing more reliable anemia correction 
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and in a shorter time [16–18]. FCM has also been compared 
with IV iron sucrose in pregnant women in a retrospective, 
observational study [19]. Here, the mean increase in Hb 
levels was numerically greater with FCM (1.54 g/dL) than 
with iron sucrose (1.17 g/dL), although this difference was 
not statistically significant. What was markedly different 
was the mean follow-up between the two groups (28.4 vs 
41.2 days, respectively; P = 0.01), indicating that restora-
tion of normal Hb levels was achieved much more quickly 
with FCM [19].
In addition to hematological effectiveness, a number 
of additional benefits of FCM over FS were demonstrated 
in our study. FCM had a dramatically reduced burden of 
treatment: comparable improvements in Hb levels were 
achieved with a 12-fold lower total dose and a 12-fold 
lower duration of exposure to FCM compared with FS. 
Outside the “compliance-friendly” environment of a 
clinical trial, a high burden of treatment can result in 
low compliance of patients with their medication, sub-
sequently leading to worsening of disease and ultimately 
increased healthcare costs [20]. For some patients, a 
single dose of FCM may correct IDA with no repeated 
administration required, thereby providing a more con-
venient option than other iron treatments and poten-
tially increasing compliance. In addition, treatment with 
FCM provided holistic benefit to these women in the later 
stages of their pregnancies. Our findings demonstrated 
that improvements immediately prior to delivery in the 
vitality of pregnant women treated with FCM were clini-
cally relevant, and it is worth noting that these effects 
were evident using a generic quality-of-life assessment 
tool, SF-36, that was not specifically designed for applica-
tion in anemic populations. It should be noted that study 
participants were not blinded to treatment and, there-
fore, the assessment of quality-of-life could have been 
influenced by subject bias. However, our findings are 
in accordance with those from a previous randomized, 
controlled trial in which FCM was found to significantly 
improve symptomatic fatigue in iron-deficient women 
[21]. Increased vitality can be of particular benefit in 
coping with the extreme physical stresses experienced 
by women during pregnancy and childbirth.
FCM was well tolerated in pregnant women during 
their second and third trimesters. The safety profile was 
consistent with what has been previously reported [16–
18, 22] and there were no unexpected safety concerns. 
As expected, treatment with FCM led to fewer gastroin-
testinal adverse events than FS; this considerable and 
clinically relevant lower burden of gastrointestinal com-
plications is likely to be beneficial to the overall feeling 
of wellbeing and quality of life for women in the late 
stages of pregnancy. Gastrointestinal TEAEs led to dis-
continuation of FS in five women in our study and, as 
previously mentioned, such non-compliance increases 
the risk of IDA recurrence in these women. The frequen-
cies of serious TEAEs experienced after FCM treatment 
in this trial (which included “failed trial of labor”, “fetal 
distress syndrome”, “premature delivery” and “prema-
ture rupture of membranes”) are in line with those seen 
in a recent Cochrane review of iron supplementation in 
pregnant women (pregnant women receiving placebo or 
no treatment: preterm birth, 7.3%; premature rupture of 
membranes, 12.2%; pre-eclampsia, 2.2%) [23]. Bronchos-
pasm occurred in one woman treated with FCM that led to 
treatment withdrawal; this was considered to be a tran-
sient hypersensitivity reaction that resolved following 
discontinuation. Parenterally administered iron prepara-
tions can cause hypersensitivity reactions and bronchos-
pasm is recognized as an adverse event that can occur 
rarely with ferric carboxymaltose treatment and is listed 
in the approved label [rare event ( ≥ 1/10,000 to  < 1/1000 of 
the treated population)] [24].
No complications associated with FCM treatment of 
the mothers were evident in the newborns. Cord serum 
ferritin levels were found to be numerically (although 
not statistically significantly) higher following FCM treat-
ment, compared with oral iron treatment. Such cord serum 
ferritin levels reflect good iron reserves in the newborns 
for growth and development, thereby diminishing the 
risk of ID that can have important implications on infant 
morbidity and ongoing brain development and behavior 
[25]. Conversely, excessive levels of serum ferritin could 
indicate iron overload that can lead to serious complica-
tions for the newborn [25]. Such excessive levels were not 
observed in this study – all newborns of mothers treated 
with FCM had serum ferritin levels that fell within normal 
ranges [26, 27] and were completely healthy.
Conclusions
During the second and third trimesters, FCM has com-
parable efficacy to first-line oral iron treatment and is 
well tolerated in pregnant women with no complications 
evident in their newborns. In late-stage pregnancy, when 
time to delivery is a limiting step, administration of FCM 
may be a more appropriate option than oral iron for rapid 
and effective anemia correction. FCM is also a valuable 
alternative for pregnant women who lack a response to, 
are non-compliant with, or are intolerant of oral iron treat-
ment, as well as those who have severe IDA.
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